Strong Financial Performance: Novartis reported a robust Q2 2025 performance with net sales up 11% and core operating income up 21%, resulting in an upgrade of full-year guidance for core operating income growth to the low teens (13%-14%) instead of the previous low double digits (10%-12%). Core EPS was reported at $2.42, an increase of 24% year-over-year, alongside a significant cash flow of $6.3 billion, up 37%.

Product Highlights and Growth Drivers: Key brands exhibited substantial growth: - Kisqali grew by 64%, achieving leadership in metastatic and early breast cancer indications. - Leqvio grew by 61%, with a strong performance driven by new data and increased market share. - Pluvicto returned to robust growth with 30% increase driven by new indications and expanded treatment sites. - Scemblix grew by 79%, with high momentum in early lines of therapy expected to exceed $1 billion in sales.

Future Focus on Innovation: Novartis emphasized its commitment to innovation with important pipeline milestones, including submissions for OAV101, significant progress in Huntington's disease treatments, and promising Phase II results for Remibrutinib in food allergies, indicating a potential for new treatment options in high-need areas.